Your browser is no longer supported. Please, upgrade your browser.
Settings
IHE iShares US Pharmaceuticals daily Stock Chart
IHE [NYSE]
iShares US Pharmaceuticals
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week-4.37%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month2.31%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-6.22%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio4.66 Perf Half Y-7.18%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-11.45%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range128.65 - 163.39 Perf YTD-13.80%
Dividend1.41 P/FCF- EPS past 5Y- ROI- 52W High-15.26% Beta-
Dividend %1.02% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low7.63% ATR2.90
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)39.61 Volatility1.71% 2.02%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.42 Prev Close137.31
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume48.75K Price138.46
Recom- SMA20-2.72% SMA50-4.30% SMA200-4.35% Volume20,500 Change0.84%
Dec-02-16 04:05PM  Two Nano-Cap Pharma Stocks To Watch Right Now at Insider Monkey
Nov-29-16 10:05AM  Pfizer Divests Hospiras Infusion System Business to ICU Medical
Nov-17-16 12:18PM  Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios
Nov-16-16 05:04PM  Novartiss 3Q16 Earnings Surpass Analyst Estimates
Nov-09-16 10:08AM  Trump Victory Big For Biotech at Barrons.com +6.89%
Nov-08-16 10:04AM  Pfizers 3Q16 Earnings: Profitability and Financial Guidance
08:04AM  Understanding Pfizers Products with Declining Sales
Nov-07-16 10:02AM  Healthcare ETFs in the Spotlight as Election Approaches
Nov-01-16 08:04AM  Behind the Recent Developments in Pfizers 3Q16 Estimates
Oct-28-16 12:07PM  3 ETFs to Buy if You Think Pfizer Will Beat Earnings
Oct-25-16 11:45AM  Bristol-Myers Squibbs 3Q16 Earnings: Whats Expected
10:04AM  Analyzing Future Estimates for Johnson & Johnson
Oct-21-16 10:05AM  A Look at Johnson & Johnsons Segment-Wise Performance in 3Q16
Oct-14-16 11:04AM  How Much Is Pfizers Return Potential?
10:10AM  Johnson & Johnsons 3Q16 Earnings: What to Expect
10:04AM  Pfizers Divestment of Hospira Infusion Systems
Oct-11-16 08:04AM  What Do Analysts Have to Say about Bristol-Myers Squibb?
Oct-03-16 08:05AM  Medicare Negotiations Would Lead to Huge Cost Savings
Sep-30-16 03:04PM  Analyzing Donald Trumps Free-Market Healthcare
01:04PM  How Does Hillary Clinton Plan to Tame Drug Prices?
11:15AM  Generic Drugs Are Crucial in Cost Savings and Accessibility
Sep-29-16 06:04PM  The Pfizer-Anacor Deal: A Review
Sep-27-16 02:20PM  Getting Into The Drug Business: From NDAs To PDUFA Dates
Sep-23-16 05:04PM  Youve Heard about the EpiPen Debacle, but Have You Heard This?
Sep-21-16 10:04AM  How Procysbi Fits into Horizons Existing Orphan Drug Portfolio
Sep-12-16 10:04AM  How Can Pfizer Revive Its Essential Health Business?
09:30AM  The Zacks Analyst Blog Highlights: Powershares Dynamic Pharmaceuticals ETF, SPDR S&P Pharmaceuticals ETF, iShares U.S. Pharmaceuticals and Market Vectors Pharmaceutical
Sep-09-16 03:39PM  Will a Clinton Presidency Spell Doom for Pharma ETFs?
Sep-01-16 11:04AM  Why Pfizers Vaccines Business Is Declining
Aug-31-16 11:05AM  Will Xtandi Fuel Pfizers Top-Line Growth?
10:58AM  Biotech Leads the Way in Health Care Stocks to Boost 401(k) Returns
Aug-30-16 02:04PM  Analyzing Johnson & Johnsons Business Segments
Aug-22-16 12:01PM  ETFs in Focus on Pfizer's Medivation Acquisition
Aug-11-16 11:04AM  Pfizers Products with Decreasing Revenues
Aug-05-16 09:05AM  Falls Continue in Specialty Generics and Nuclear Imaging
Aug-03-16 12:22PM  Pharma ETFs Soaring on Solid Q2 Earnings
Jul-27-16 09:04AM  What Do Analysts Estimate for Johnson & Johnson?
Jul-22-16 01:14PM  How Did Johnson & Johnsons Segments Perform in 2Q16?
Jul-14-16 10:06AM  How Can Celators Portfolio Complement Jazz Pharmaceuticals?
Jul-04-16 11:06AM  Insights into Pfizers Profitability and Financial Guidance
09:07AM  Pfizers Products with Declining Revenues: What Does That Mean?
Jun-30-16 03:07PM  What the CHMP Just Recommended for Alkems Riluzole Alkem
03:07PM  What the CHMP Just Recommended for Alkems Riluzole Alkem at Market Realist
Jun-29-16 09:08AM  Inside the CHMPs Refusal of Novartiss Arzerra as a Maintenance Treatment
Jun-28-16 11:06AM  Mylans Key Developments and Big Plans: What You Should Know
Jun-04-16 06:00PM  Why This Healthcare ETF Was Last Week's Biggest Winner at Motley Fool
Jun-02-16 11:00AM  Trending on ETFdb.com: Emerging Markets and Dividend Kings Garner Interest
May-27-16 11:37AM  Government Study: Cellphone Radiation Linked To Cancer
May-14-16 03:52PM  Last Week's Best Healthcare ETF at Motley Fool
May-11-16 09:07AM  Pfizers 1Q16 Earnings: Profitability and Financial Guidance Market Realist
May-10-16 09:07AM  What to Expect from Mallinckrodts Specialty Generics Business Market Realist
May-09-16 04:07PM  Pfizers 1Q16 Earnings: Products That Saw Sales Drop Market Realist
May-07-16 10:01AM  Mudslinging Over Valeant Pharmaceuticals
May-04-16 02:50PM  Pharma ETFs Outlook -- Drug Pricing Issues Remain in Focus
09:00AM  Finding Pharmaceuticals ETFs With Rebound Potential
May-02-16 04:16PM  The Last Week of April Wasnt Good for Biotechnology Stocks
Apr-28-16 10:06AM  Fertilizer Impact: Natural Gas Prices Rise Yet Again for Week Ending April 22
Apr-25-16 08:06PM  A Segment-by-Segment Breakdown of JNJs 1Q16 Earnings
Apr-06-16 01:05AM  Behind Horizons EV-to-EBITDA Performance
Apr-04-16 07:05AM  What Do Analysts Expect for Pfizers Profitability?
Apr-01-16 04:08PM  Checkmate-205: Studies Supporting Opdivos Application
Mar-31-16 05:26PM  Opdivo: Bristol-Myers Squibbs Blockbuster Drug
09:08AM  Why Actimmune, Horizons Lead Orphan Product, Has Such Huge Potential
Mar-28-16 02:06PM  How Is Meda AB a Strategic Fit for Mylans Business?
02:06PM  Mallinckrodt in 2016: Whats on the Horizon?
Mar-23-16 11:05AM  Understanding Future Estimates for Johnson & Johnson
Mar-18-16 02:54PM  Johnson & Johnsons 1Q16 Earnings: Whats Expected
Mar-12-16 09:30PM  Last Week's Best Healthcare ETF at Motley Fool
Mar-11-16 04:04PM  Bristol-Myers Squibb: What Do Its Other Segments Offer?
Mar-10-16 12:04PM  Bristol-Myers Squibbs Opdivo: Why Is It Important?
Mar-09-16 09:05PM  A Look at Bristol-Myers Squibbs Oncology Segment
09:04PM  How Has Technology Influenced Process and Product Innovation?
06:37AM  5 Best Performing Bull Run Equity ETFs
Mar-03-16 01:58PM  Drug Patent Expirations: $190 Billion Is Up for Grabs
Mar-02-16 04:10PM  Other Industries That Depend on Specialty Chemicalsand Why
08:43AM  Will Generic Drugs Help Curb Healthcare Costs?
Mar-01-16 02:41PM  Look Beyond Pharma to Opportunities in Generics!
Feb-06-16 01:15PM  Last Week's Best Healthcare ETF at Motley Fool
Jan-04-16 01:50PM  What Does 2016 Hold in Store for Pharma ETFs
Dec-31-15 12:06AM  How Will Johnson & Johnsons Pharmaceutical Segment Do in 4Q15?
Dec-29-15 02:25PM  IYZ Sees $57.2 Million in Fund Outflows in Trailing 12 Months Market Realist
08:11AM  What to Expect from Johnson & Johnsons 4Q15 Earnings
Dec-17-15 02:51PM  IYZ Sees $59.3 Million in Fund Inflows in Trailing 12 Months Market Realist
Dec-16-15 04:59PM  The iShares US Medical Devices ETF (IHI) Has Put Nothing under the Tree in DecemberYet
Dec-11-15 10:07AM  Market Response to Johnson & Johnsons Press Program
09:06AM  IYW Sees $61.7 Billion in Fund Inflows in Trailing 1 Month
Dec-04-15 08:58AM  Eloquent-2: Clinical Study Supports Emplicitis Approval
Dec-02-15 01:04PM  The Markets Response to Avelumabs Breakthrough Designation
Nov-26-15 01:58PM  CheckMate -025 Study Supports Opdivos Approval
01:58PM  FDA Approves Opdivo for Additional Indications
Nov-23-15 02:34PM  JAVELIN Series: Clinical Studies of Avelumab
02:34PM  Avelumab Receives Breakthrough Therapy Designation
10:08AM  Existing Drugs for Renal Cell Carcinoma
Nov-20-15 10:43AM  Studies Supporting Opdivos sBLA for Renal Cell Carcinoma
10:42AM  Opdivos sBLA Accepted by FDA for Priority Review
Nov-19-15 09:29AM  Pfizer in Talks to Buy Allergan: Prescribed ETFs
Nov-09-15 02:10PM  Don't Abandon Preferred ETFs
Nov-06-15 10:17AM  Crude Oil Rig Count: Will It Fuel Optimism in the Crude Oil Market?
Nov-02-15 04:59PM  IBB Was among the Best Biotechnology ETFs for the Week
06:47AM  ETF Week Ahead Preview: Hoping For No November Rain
The investment seeks to track the investment results of Dow Jones U.S. Select Pharmaceuticals Index. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying fund measures the performance of the pharmaceuticals sector of the U.S. equity market and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The fund is non-diversified.